Barnes, Worthy To Speak at NC Substance Misuse Prevention Conference

Michael C. Barnes, JD, and Stacey L. Worthy, JD, both Principal Attorneys at Sequel Legal, are slated to speak at the 2021 North Carolina Prevention Conference. Mr. Barnes will co-present with David Ezzell, MPA, Education Consultant and Paramedic with the North Carolina Office of Emergency Medical Services. Their presentation, entitled, “Community Paramedicine: Mobilizing Resources in […]

Barnes To Speak at Pharmacists’ Institute on Substance Use Disorders

Michael C. Barnes, JD, Principal Attorney at Sequel Legal and Chairman of the Center for U.S. Policy, will speak at the American Pharmacists Association (APhA) 2021 Institute on Substance Use Disorders on Tuesday, June 1. Mr. Barnes will update his presentation from the APhA 2021 Annual Meeting entitled “Don’t ‘Just Say No’: Preventing Diversion and Addressing Medical Needs.” He will co-present with Jake Nichols, PharmD, CEO […]

Barnes To Moderate at 2021 Rx Summit

Michael C. Barnes, JD, Principal Attorney at Sequel Legal and Chairman of the Center for U.S. Policy, will moderate three separate sessions at the 2021 Rx Drug Abuse & Heroin Summit. Topics will include informed addiction policy, post-overdose interventions, and addressing social determinants of health in addiction treatment. The annual conference will take place online April 5-8.  Registration for 2021 Rx Summit is still open, and the full agenda is […]

Barnes To Speak at 2021 Pharmacist Conference

Michael C. Barnes, JD, Principal Attorney at Sequel Legal and Chairman of the Center for U.S. Policy, will speak at the American Pharmacists Association (APhA) 2021 Annual Meeting on Monday, March 15. Mr. Barnes will co-present the session, entitled “Don’t ‘Just Say No’: Preventing Diversion and Addressing Medical Needs,” with Jake Nichols, PharmD, CEO of Professional Recovery Resources. Mr. Barnes will provide an overview of federal and state […]

DEA Temporarily Relaxes Telemedicine Standards for Prescribing Buprenorphine During COVID-19 Outbreak

The Drug Enforcement Administration (DEA) has temporarily relaxed the federal requirements for prescribing buprenorphine for opioid use disorder (OUD) via telemedicine during the COVID-19 public health emergency. As a general rule, the federal Controlled Substances Act (CSA) requires a valid prescription before a controlled prescription medication may be delivered, distributed, or dispensed by means of […]